More evidence further indicates that the TME of HRD cancers is characterized by molecular alterations across four critical pathways: (1) dynamic regulation of antigen-presenting capacity, (2) upregulation of IFN signaling, (3) activation of the JAK-STAT pathway, and (4) metabolic reprogramming centered on energy utilization (Fig. 3). The gene discussed is SOAT1; the disease is cancer.